When it comes to improving diversity and inclusion in clinical trials, while many companies have acted in response to COVID-19 and the way the pandemic highlighted structural deficiencies across the drug-development landscape, the messenger RNA-focused biotech Moderna, Inc. made some notable strides in its vaccine development plan.
Early on, in an effort to promote transparency, Moderna became the first to publish, without redactions, the protocol for its Phase III COVE study of its COVID-19 vaccine mRNA-1273 while the study was underway
Citeline Award Nominee
Scrip is interviewing the companies shortlisted for the inaugural champion of diversity and inclusion in clinical research award, to highlight some of the best practices in this urgent area. The series kicked off with a profile of Novavax
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?